Valerio Therapeutics Société anonyme (EPA:ALVIO)

Market Cap	10.12M
Revenue (ttm)	1.89M
Net Income (ttm)	-19.66M
Shares Out	153.97M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,013
Average Volume	125,142
Open	0.0630
Previous Close	0.0631
Day's Range	0.0630 - 0.0660
52-Week Range	0.0401 - 0.1398
Beta	1.83
RSI	52.97
Earnings Date	Jun 27, 2025

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 19
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVIO

Financial Performance

In 2023, EPA:ALVIO's revenue was 1.80 million, an increase of 24.74% compared to the previous year's 1.44 million. Losses were -20.34 million, 4.00% more than in 2022.